Other approaches to expand efficacy of HGF/c-Met targeting include combining these agents with inhibitors of the viability or function of stromal cells such as tumor-associated fibroblasts, endothelial cells, or macrophages, or using immunotherapy in combination with HGF/c-Met agents. This evidence concerns the gene MET and neoplasm.